163 related articles for article (PubMed ID: 19622716)
1. Cost-effectiveness of diabetes self-management programs in community primary care settings.
Brownson CA; Hoerger TJ; Fisher EB; Kilpatrick KE
Diabetes Educ; 2009; 35(5):761-9. PubMed ID: 19622716
[TBL] [Abstract][Full Text] [Related]
2. Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis.
Gillett M; Dallosso HM; Dixon S; Brennan A; Carey ME; Campbell MJ; Heller S; Khunti K; Skinner TC; Davies MJ
BMJ; 2010 Aug; 341():c4093. PubMed ID: 20729270
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: impact of modelling assumptions on recent Canadian findings.
Tunis SL
Appl Health Econ Health Policy; 2011 Nov; 9(6):351-65. PubMed ID: 21892840
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of automated telephone self-management support with nurse care management among patients with diabetes.
Handley MA; Shumway M; Schillinger D
Ann Fam Med; 2008; 6(6):512-8. PubMed ID: 19001303
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand.
Permsuwan U; Chaiyakunapruk N; Dilokthornsakul P; Thavorn K; Saokaew S
Appl Health Econ Health Policy; 2016 Jun; 14(3):281-92. PubMed ID: 26961276
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis for a tele-based health coaching program for chronic disease in primary care.
Oksman E; Linna M; Hörhammer I; Lammintakanen J; Talja M
BMC Health Serv Res; 2017 Feb; 17(1):138. PubMed ID: 28202032
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes.
van Giessen A; Boonman-de Winter LJ; Rutten FH; Cramer MJ; Landman MJ; Liem AH; Hoes AW; Koffijberg H
Cardiovasc Diabetol; 2016 Mar; 15():48. PubMed ID: 27001409
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
Palmer JL; Gibbs M; Scheijbeler HW; Kotchie RW; Nielsen S; White J; Valentine WJ
Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
[TBL] [Abstract][Full Text] [Related]
9. Medicare's intensive behavioral therapy for obesity: an exploratory cost-effectiveness analysis.
Hoerger TJ; Crouse WL; Zhuo X; Gregg EW; Albright AL; Zhang P
Am J Prev Med; 2015 Apr; 48(4):419-25. PubMed ID: 25703178
[TBL] [Abstract][Full Text] [Related]
10. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.
Palmer AJ; Tucker DM
Prim Care Diabetes; 2012 Jul; 6(2):109-21. PubMed ID: 22153888
[TBL] [Abstract][Full Text] [Related]
11. Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US.
Tunis SL; Minshall ME
Curr Med Res Opin; 2010 Jan; 26(1):151-62. PubMed ID: 19919376
[TBL] [Abstract][Full Text] [Related]
12. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
Ray JA; Boye KS; Yurgin N; Valentine WJ; Roze S; McKendrick J; Tucker DM; Foos V; Palmer AJ
Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis.
Howard K; White S; Salkeld G; McDonald S; Craig JC; Chadban S; Cass A
Value Health; 2010; 13(2):196-208. PubMed ID: 19878493
[TBL] [Abstract][Full Text] [Related]
14. Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: a US analysis based on PROactive.
Valentine WJ; Tucker D; Palmer AJ; Minshall ME; Foos V; Silberman C;
Value Health; 2009; 12(1):1-9. PubMed ID: 18657104
[TBL] [Abstract][Full Text] [Related]
15. Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes.
Palmer AJ; Dinneen S; Gavin JR; Gray A; Herman WH; Karter AJ
Curr Med Res Opin; 2006 May; 22(5):861-72. PubMed ID: 16709308
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.
Viriato D; Calado F; Gruenberger JB; Ong SH; Carvalho D; Silva-Nunes J; Johal S; Viana R
J Med Econ; 2014 Jul; 17(7):499-507. PubMed ID: 24708176
[TBL] [Abstract][Full Text] [Related]
17. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
Tunis SL; Willis WD; Foos V
Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of a brief education, self-management and upper limb exercise training in people with rheumatoid arthritis (EXTRA) programme: a trial-based analysis.
Manning VL; Kaambwa B; Ratcliffe J; Scott DL; Choy E; Hurley MV; Bearne LM
Rheumatology (Oxford); 2015 Feb; 54(2):302-9. PubMed ID: 25173349
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea.
Lee KH; Seo SJ; Smith-Palmer J; Palmer JL; White J; Valentine WJ
Value Health; 2009; 12 Suppl 3():S55-61. PubMed ID: 20586983
[TBL] [Abstract][Full Text] [Related]
20. Telemonitoring and self-management in the control of hypertension (TASMINH2): a cost-effectiveness analysis.
Kaambwa B; Bryan S; Jowett S; Mant J; Bray EP; Hobbs FD; Holder R; Jones MI; Little P; Williams B; McManus RJ
Eur J Prev Cardiol; 2014 Dec; 21(12):1517-30. PubMed ID: 23990660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
